FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Go back to FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 216.12 +6.38 (3.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $209.74 | 52 Week High | $333.65 | |||
| Open | $212.74 | 52 Week Low | $223.02 | |||
| Day High | $219.02 | P/E | 27.67 | |||
| Day Low | $210.75 | EPS | $7.81 | |||
| Volume | 1,155,165 | |||||
